Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats

Neurotherapeutics

Volumn 12, Issue 1, 2015, Pages 250-262

  Citraro, Rita ^a   Leo, Antonio ^a   Aiello, Rossana ^a   Pugliese, Michela ^b   Russo, Emilio ^a   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Aripiprazole; Audiogenic seizures; Clozapine; Haloperidol; Olanzapine; Quetiapine

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; EPILEPSY; GENETICS; MENTAL DISORDERS; RAT; SEIZURE;

ANIMALS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BENZODIAZEPINES; CLOZAPINE; DISEASE MODELS, ANIMAL; EPILEPSY; HALOPERIDOL; MENTAL DISORDERS; QUETIAPINE FUMARATE; RATS; RISPERIDONE; SEIZURES;

EID: 84930210412     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0318-6     Document Type: Article

References (95)

1. Marks RC, Luchins DJ. Antipsychotic medications and seizures. Psychiatr Med 1991;9:37-52.
2. Trifiro G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab 2011;12:611-620.
3. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000;61(Suppl. 8):5-11.
4. Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G. Conventional and atypical antipsychotics in the elderly: A review. Clin Drug Investig 2003;23:287-322.
5. Gareri P, De Fazio P, De Fazio S, et al. Adverse effects of atypical antipsychotics in the elderly: A review. Drugs Aging 2006;23:937-956.
6. Gareri P, De Fazio P, Russo E, Marigliano N, De Fazio S, De Sarro G. The safety of clozapine in the elderly. Expert Opin Drug Saf 2008;7:525-538.
7. Alldredge BK. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999;53:S68-75.
8. Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, Garcia M, Aguirre C. Antipsychotics and seizures: higher risk with atypicals? Seizure 2013;22:141-143.
9. Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today (Barc) 2003;39:551-557.
10. Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol 2012;11:1093-1102.
11. Kanner AM, Schachter SC, Barry JJ, et al. Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav 2012;24:156-168.
12. Kanner AM. Is depression a risk factor of worse response to therapy in epilepsy? Epilepsy Curr 2011;11:50-51.
13. Kanner AM. Depression and epilepsy: A bidirectional relation? Epilepsia 2011;52(Suppl. 1):21-27.
14. Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol 2006;59:35-41.
15. Lomas J, Boardman RH, Markowe M. Complications of chlorpromazine therapy in 800 mental-hospital patients. Lancet 1955;268:1144-1147.
16. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58(Suppl. 10):55-62.
17. Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 2010;19:69-73.
18. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002;25:91-110.
19. Stevens JR, Denney D, Szot P. Kindling with clozapine: behavioral and molecular consequences. Epilepsy Res 1996;26:295-304.
20. Celikyurt IK, Kayir H, Ulak G, Erden FB, Ulusoy GK, Uzbay TI. Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:528-536.
21. Kayir H, Uzbay T. Effects of clozapine on ethanol withdrawal syndrome in rats. Alcohol Alcohol 2008;43:619-625.
22. Unsalan N, Saglam E, Kayir H, Uzbay T. Effects of olanzapine on ethanol withdrawal syndrome in rats. Eur J Pharmacol 2008;579:208-214.
23. Russo E, Citraro R, Davoli A, Gallelli L, Di Paola ED, De Sarro G. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2013;64:371-379.
24. Faingold CL. Neuronal networks in the genetically epilepsy-prone rat. Adv Neurol 1999;79:311-321.
25. De Sarro G, De Sarro A, Ammendola D, Patel S. Lack of development of tolerance to anticonvulsant effects of two excitatory amino acid antagonists, CGP [corrected] 37849 and CGP 39551 in genetically epilepsy-prone rats. Brain Res 1996;734:91-97.
26. De Sarro A, Grasso S, Zappala M, Nava F, De Sarro G. Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats. Naunyn Schmiedebergs Arch Pharmacol 1997;356:48-55.
27. Dailey JW, Reigel CE, Mishra PK, Jobe PC. Neurobiology of seizure predisposition in the genetically epilepsy-prone rat. Epilepsy Res 1989;3:3-17.
28. Mishra PK, Dailey JW, Reigel CE, Jobe PC. Audiogenic convulsions in moderate seizure genetically epilepsy-prone rats (GEPR-3s). Epilepsy Res 1989;3:191-198.
29. Reigel CE, Jobe PC, Dailey JW, Savage DD. Ontogeny of sound-induced seizures in the genetically epilepsy-prone rat. Epilepsy Res 1989;4:63-71.
30. Reigel CE, Dailey JW, Jobe PC. The genetically epilepsy-prone rat: an overview of seizure-prone characteristics and responsiveness to anticonvulsant drugs. Life Sci 1986;39:763-774.
31. Dailey JW, Jobe PC. Anticonvulsant drugs and the genetically epilepsy-prone rat. Fed Proc 1985;44:2640-2644.
32. De Sarro GB, De Sarro A. Anticonvulsant properties of non-competitive antagonists of the N-methyl-D-aspartate receptor in genetically epilepsy-prone rats: comparison with CPPene. Neuropharmacology 1993;32:51-58.
33. De Sarro A, De Sarro GB. Responsiveness of genetically epilepsy-prone rats to aminophylline-induced seizures and interactions with quinolones. Neuropharmacology 1991;30:169-176.
34. Jobe PC, Picchioni AL, Chin L. Role of brain norepinephrine in audiogenic seizure in the rat. J Pharmacol Exp Ther 1973;184:1-10.
35. Jobe PC, Mishra PK, Ludvig N, Dailey JW. Scope and contribution of genetic models to an understanding of the epilepsies. Crit Rev Neurobiol 1991;6:183-220.
36. Citraro R, Scicchitano F, De Fazio S, et al. Preclinical activity profile of alpha-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. Epilepsy Res 2011;95:60-69.
37. Mishra PK, Dailey JW, Reigel CE, Jobe PC. Brain norepinephrine and convulsions in the genetically epilepsy-prone rat: Sex-dependent responses to Ro 4-1284 treatment. Life Sci 1988;42:1131-1137.
38. Jobe PC, Dailey JW, Reigel CE. Noradrenergic and serotonergic determinants of seizure susceptibility and severity in genetically epilepsy-prone rats. Life Sci 1986;39:775-782.
39. Gareri P, Condorelli D, Belluardo N, et al. Anticonvulsant effects of carbenoxolone in genetically epilepsy prone rats (GEPRs). Neuropharmacology 2004;47:1205-1216.
40. Russo E, Citraro R, Scicchitano F, et al. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia 2011;52:1341-1350.
41. Minabe Y, Watanabe K, Nishimura T, Ashby CR, Jr. Acute and chronic administration of clozapine produces greater proconvulsant actions than haloperidol on focal hippocampal seizures in freely moving rats. Synapse 1998;29:272-278.
42. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2003;306:1145-1151.
43. Ortega-Alvaro A, Gibert-Rahola J, Mico JA. Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:104-111.
44. Russo E, Citraro R, Scicchitano F, et al. Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. Epilepsia 2010;51:1560-1569.
45. Russo E, Citraro R, Scicchitano F, et al. Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. Behav Brain Res 2011;225:373-376.
46. Russo E, Citraro R, Donato G, et al. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 2013;69:25-36.
47. Citraro R, Chimirri S, Aiello R, et al. Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. Epilepsia 2014;55:1284-1291.
48. Jobe PC, Dailey JW. Neurobiology of seizure predisposition in the genetically epilepsy prone rat. Proc West Pharmacol Soc 1991;34:223-225.
49. Russo E, Donato di Paola E, Gareri P, et al. Pharmacodynamic potentiation of antiepileptic drugs’ effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice. Pharmacol Res 2013;70:1–12.
50. De Sarro G, Trimarchi GR, Federico F, De Sarro A. Anticonvulsant activity of some calcium antagonists in genetically epilepsy prone rats. Epilepsy Res Suppl 1991;3:49-55.
51. Russo E, Citraro R, De Fazio S, Torcasio G, De Sarro G, Di Paola ED. Effects of ethanol on the development of genetically determined epilepsies in rats. Int J Dev Neurosci 2008;26:739-744.
52. Gareri P, Cotroneo A, Lacava R, et al. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch Gerontol Geriatr Suppl 2004:207–215.
53. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002;161:263-270.
54. Lee JW, Crismon ML, Dorson PG. Seizure associated with olanzapine. Ann Pharmacother 1999;33:554-556.
55. Tarazi FI, Florijn WJ, Creese I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience 1997;78:985-996.
56. Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology 2012;62:765-774.
57. Strange PG. Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001;53:119-133.
58. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-526.
59. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007;8:1211-1219.
60. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011;11:59-67.
61. Lerond J, Lothe A, Ryvlin P, et al. Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia. J Clin Psychopharmacol 2013;33:84-89.
62. Love RC, Nelson MW. Pharmacology and clinical experience with risperidone. Expert Opin Pharmacother 2000;1:1441-1453.
63. Yadav PN, Kroeze WK, Farrell MS, Roth BL. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther 2011;339:99-105.
64. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411.
65. Teitler M, Toohey N, Knight JA, Klein MT, Smith C. Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions. Psychopharmacology (Berl) 2010;212:687-697.
66. Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1145-1158.
67. Brosda J, Jantschak F, Pertz HH. alpha2-Adrenoceptors are targets for antipsychotic drugs. Psychopharmacology (Berl) 2014;231:801-812.
68. Kalkman HO, Loetscher E. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 2003;462:33-40.
69. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1125-1143.
70. He M, Deng C, Huang XF. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 2013;27:423-434.
71. Yokota K, Tatebayashi H, Matsuo T, et al. The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics. Br J Pharmacol 2002;135:1547-1555.
72. Yan QS, Dailey JW, Steenbergen JL, Jobe PC. Anticonvulsant effect of enhancement of noradrenergic transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): a microinjection study. Brain Res 1998;780:199-209.
73. Brennan TJ, Seeley WW, Kilgard M, Schreiner CE, Tecott LH. Sound-induced seizures in serotonin 5-HT2c receptor mutant mice. Nat Genet 1997;16:387-390.
74. Applegate CD, Tecott LH. Global increases in seizure susceptibility in mice lacking 5-HT2C receptors: a behavioral analysis. Exp Neurol 1998;154:522-530.
75. Richtand NM, Welge JA, Logue AD, Keck PE, Jr., Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007;32:1715-1726.
76. Uzbay IT. [New pharmacological approaches to the treatment of schizophrenia]. Turk Psikiyatri Derg 2009;20:175-182 (in Turkish).
77. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 1993;9:117-124.
78. Langosch JM, Trimble MR. Epilepsy, psychosis and clozapine. Hum Psychopharmacol 2002;17:115-119.
79. White DM, Van Cott AC. Clozapine (Clozaril), seizures, and EEG abnormalities. Am J Electroneurodiagnostic Technol 2007;47:190-197.
80. Uzbay TI. Atypical antipsychotic drugs and ethanol withdrawal syndrome: a review. Alcohol Alcohol 2012;47:33-41.
81. Trzaskowska E, Krzascik P, Staniszewska A, Pucilowski O, Kostowski W. On the relative importance of D-1 vs. D-2 dopaminergic receptors in the control of audiogenic seizures in ethanol withdrawn rats. Drug Alcohol Depend 1989;24:265-267.
82. Uzbay IT, Usanmaz SE, Tapanyigit EE, Aynacioglu S, Akarsu ES. Dopaminergic and serotonergic alterations in the rat brain during ethanol withdrawal: association with behavioral signs. Drug Alcohol Depend 1998;53:39-47.
83. Yu L, Fisher H, Wagner GC. Monoaminergic changes associated with audiogenic seizures in ethanol-dependent rats. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:1379-1392.
84. Yan QS, Jobe PC, Cheong JH, Ko KH, Dailey JW. Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Naunyn Schmiedebergs Arch Pharmacol 1994;350:149-152.
85. Kalkman HO, Neumann V, Hoyer D, Tricklebank MD. The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat. Br J Pharmacol 1998;124:1550-1556.
86. Yan QS, Jobe PC, Dailey JW. Noradrenergic mechanisms for the anticonvulsant effects of desipramine and yohimbine in genetically epilepsy-prone rats: studies with microdialysis. Brain Res 1993;610:24-31.
87. Acri AA, Henretig FM. Effects of risperidone in overdose. Am J Emerg Med 1998;16:498-501.
88. Gerald MC, Richter NA. Studies on the effects of histaminergic agents on seizure susceptibility in mice. Psychopharmacologia 1976;46:277-282.
89. Sturman G, Freeman P, Quinn L. Histamine H1-antagonists potentiate seizures in the EL (epilepsy-like) mouse model of temporal lobe epilepsy. Inflamm Res 2001;50(Suppl.) 2:S80-S81.
90. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006;31:1854-1863.
91. Tsai JF. Aripiprazole-associated seizure. J Clin Psychiatry 2006;67:995-996.
92. Lin KH, Chen YJ, Lin YT, et al. Serious generalized tonic-clonic seizures induced by aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:231-232.
93. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med 2013;64:393-406.
94. Woolley J, Smith S. Lowered seizure threshold on olanzapine. Br J Psychiatry 2001;178:85-86.
95. Camacho A, Garcia-Navarro M, Martinez B, Villarejo A, Pomares E. Olanzapine-induced myoclonic status. Clin Neuropharmacol 2005;28:145-147.